An Open Label, Randomized, Crossover Study To Estimate The Pharmacokinetics And Evaluate The Safety Following A Single Dose Of Azithromycin 2g Extended-Release Powder For Oral Suspension With A 3-Day Dosing Regimen Of Azithromycin 500mg Tablet In Chinese Healthy Male Subjects

An Open Label, Randomized, Crossover Study To Estimate The Pharmacokinetics And Evaluate The Safety Following A Single Dose Of Azithromycin 2g Extended-Release Powder For Oral Suspension With A 3-Day Dosing Regimen Of Azithromycin 500mg Tablet In Chinese Healthy Male Subjects

The purpose of this study is to estimate the pharmacokinetics and evaluate the safety following a single dose of azithromycin 2g extended-release powder for oral suspension with a 3-day dosing regimen of azithromycin 500mg tablet in Chinese healthy male subjects. This study data will be used to support azithromycin NDA in China.

Inclusion Criteria:

• Healthy volunteers.
• Male.
• 18-45 years old.
• BMI 17.5-30.5 kg/m2.

Exclusion Criteria:

• Alcohol, drug, smoke user.
• Sensitive to macrolide antibiotics class drug, parn or heparin-induced thrombocytopenia.
• Severe medical or psychiatric condition or laboratory abnormality.
• Blood donation.
• 12-ECG abnormal.
• Treatment with study drug; clinically significant.